KMDA

Kamada Ltd.

5.88 USD

Last updated Dec 10, 16:03 UTC

Yesterday HIGH

$5.85

Yesterday LOW

$5.7

52w HIGH

$6.35

52w LOW

$3.72

EPS

0.06

PE

98.00

Next Earnings

Mar 13, 2024

Overview News Government Trades

Kamada Ltd. stock is up 25.64% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 December’s closed higher than November. 100% of analysts rate it a buy.

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD. It also provides Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Rehovot, Israel

Website

kamada.com

Benzinga Newsdesk

Wed May 24, 2023

Kamada Q1 EPS $0.04 Beats $0.02 Estimate, Sales $30.71M Miss $34.30M Estimate

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 200 percent increase over losses of $(0.04) per share from the same period
Benzinga Newsdesk

Wed May 24, 2023

Kamada Announces A $60M Private Placement With FIMI Opportunity Funds
Benzinga Newsdesk

Wed May 24, 2023

Kamada Announces $60M Private Placement With FIMI Opportunity Funds
Benzinga Insights

Tue May 23, 2023

Kamada Earnings Preview
Benzinga Insights

Wed May 17, 2023

Earnings Scheduled For May 17, 2023

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is likely to report quarterly earnings at $0.14 per share on revenue of $369.35 million.
Benzinga Insights

Tue May 16, 2023

Kamada Earnings Preview
Benzinga Newsdesk

Tue May 16, 2023

Kamada Announces Receipt Of Marketing Authorization For Glassia For Treatment Of Alpha-1 Antitrypsin Deficiency In Switzerland
richadhand@benzinga.com

Thu Mar 16, 2023

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Kamada (NASDAQ:KMDA) with a Buy and maintains $11 price target.
Benzinga Newsdesk

Wed Mar 15, 2023

Kamada Expects FY23 Revenues Of $138M-$146M Vs. Consensus Of $147.21M

The company expects 2023 EBITDA of $22 million to $26 million; mid-point expected EBITDA represents approximately 35% growth year-over-year.
Benzinga Newsdesk

Wed Mar 15, 2023

Kamada Q4 EPS $0.07 Beats $0.06 Estimate, Sales $45.44M Beat $44.64M Estimate

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.06 by 16.67 percent. This is a 163.64 percent increase over losses of $(0.11) per share from the same